| Literature DB >> 22605992 |
Shih-Jen Lu1,2, Fok-Ching Chong1.
Abstract
Control of flavonoid derivatives inhibitors release through the inhibition of neuraminidase has been identified as a potential target for the treatment of H1N1 influenza disease. We have employed molecular dynamics simulation techniques to optimize the 2009 H1N1 influenza neuraminidase X-ray crystal structure. Molecular docking of the compounds revealed the possible binding mode. Our molecular dynamics simulations combined with the solvated interaction energies technique was applied to predict the docking models of the inhibitors in the binding pocket of the H1N1 influenza neuraminidase. In the simulations, the correlation of the predicted and experimental binding free energies of all 20 flavonoid derivatives inhibitors is satisfactory, as indicated by R(2) = 0.75.Entities:
Keywords: H1N1; molecular docking; molecular dynamics; neuraminidase
Mesh:
Substances:
Year: 2012 PMID: 22605992 PMCID: PMC3344228 DOI: 10.3390/ijms13044496
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Figure 1RMSD profiles of 20 flavonoid derivatives.
Figure 2The snapshot of the 2009 H1N1 neuraminidase of the inhibitor 1.
Important results: Important residues of the 2009 H1N1 neuraminidase from the molecular docking and molecular dynamics (MD) simulations.
| Inhibitors | Hydrogen bonding–related residues | Non-bonding contact-related residues |
|---|---|---|
| 1(A) | Trp179, Thr226, Asn295 | Tyr402 |
| 2(A) | Glu277, Asn295 | Null |
| 3(A) | Glu119, Asn295 | Null |
| 4(B) | Glu119, Ser180, Glu228, Asp294, Val346 | Null |
| 5(B) | Val346 | Null |
| 6(B) | Arg152, Glu228, Glu277 Asn295 | Null |
| 7(B) | Asn295 | Trp179, Ile223 |
| 8(B) | Glu119, Ser180, Glu228, Asp294, Val346 | Null |
| 9(B) | Arg152, Glu228, Val346 | Null |
| 10(B) | Ser180, Thr226, Glu228, Asp294 | Null |
| 11(B) | Glu228, Glu277 | Null |
| 12(B) | Asp151, Glu277, Asn325, Val346, Ser366 | Null |
| 13(B) | Trp179, Asn295 | Null |
| 14(A) | Asn295 | Null |
| 15(B) | Arg152, Trp179, Asn295 | Null |
| 16(B) | Glu119, Asp151, Ser366, Ser367, Tyr402 | Ile223, Arg368 |
| 17(B) | Trp179 | Null |
| 18(B) | Asp151, Arg152, Asn344 | Null |
| 19(B) | Asp151, Trp179, Glu228, Asn295 | Pro326 |
| 20(B) | Arg152, Trp179, Ser247, Glu277 | Null |
A: 2,3-dihydrobenzofuran backbone and B: 5,7-dihydroxychromen-4-one backbone.
Binding free energies for the 2009 H1N1 neuraminidase/flavonoid (inhibitors 1–20) complex structures by the SIE method.
| Inhibitors | Energy (kcal/mol) | |||||
|---|---|---|---|---|---|---|
| Δ | Δ | Δ | Δ | |||
| −20.7 | −9.95 | 6.12 | −6.98 | −6.825 | −7.002 | |
| −20.9 | −7.36 | 5.29 | −5.64 | −6.435 | −6.714 | |
| −15.2 | −6.69 | 4.83 | −5.71 | −5.771 | −6.518 | |
| −20.3 | −5.31 | 5.31 | −5.91 | −6.186 | −6.430 | |
| −16.9 | −6.12 | 5.81 | −7.41 | −6.071 | −6.296 | |
| −24.1 | −7.26 | 6.43 | −6.39 | −6.837 | −6.265 | |
| −20.9 | −7.36 | 5.11 | −5.43 | −6.413 | −6.014 | |
| −16.9 | −4.81 | 6.57 | −5.94 | −5.779 | −5.847 | |
| −12.9 | −4.64 | 5.11 | −5.33 | −5.277 | −5.773 | |
| −15.4 | −4.73 | 5.59 | −6.11 | −5.633 | −5.717 | |
| −13.9 | −4.91 | 6.19 | −6.82 | −5.567 | −5.629 | |
| −12.2 | −6.71 | 3.91 | −6.08 | −5.503 | −5.608 | |
| −11.4 | −5.73 | 4.41 | −4.91 | −5.193 | −5.519 | |
| −12.4 | −5.12 | 5.25 | −5.51 | −5.291 | −5.489 | |
| −15.4 | −4.73 | 5.65 | −6.41 | −5.766 | −5.450 | |
| −9.3 | −8.73 | 6.81 | −5.56 | −5.353 | −5.343 | |
| −12.9 | −4.32 | 4.81 | −5.09 | −5.221 | −5.226 | |
| −12.7 | −4.21 | 4.61 | −4.84 | −5.163 | −5.225 | |
| −11.6 | −4.29 | 4.82 | −5.11 | −5.084 | −5.199 | |
| −10.1 | −4.33 | 4.99 | −4.97 | −4.916 | −5.007 | |
Figure 3Predicted binding free energies versus experimentally determined binding free energies of the 20 inhibitors. The correlation constant (R2) is equal to 0.75. The inhibitors 1–3 and 14 (red) belong to the 2,3-dihydrobenzofuran backbone inhibitors and the others belong to the 5,7-dihydroxychromen-4-one backbone inhibitors (black).